Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 7.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - foscarnet sodium, quantity: 24 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - treatment of cytomegalovirus (cmv) retinitis in patients with the acquired immunodeficiency syndrome (aids). indications as at 11 november 1994: for treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids); and treatment of aciclovir resistant herpes simplex virus (hsv) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (hiv) infection. note: the indication for treatment of aciclovir resistant hsv infections in immunocompromised patients with hiv infections is based primarily on the results of one open label comparative study. this was of patients with hiv infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. eight patients were randomised to foscarnet (40mg/kg iv given eight hourly) and 6 were randomised to vidarabine 15mg/kg iv daily. the results showed a significant difference in favour o

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide phosphate, quantity: 1136 mg (equivalent: etoposide, qty 1000 mg) - injection, powder for - excipient ingredients: sodium citrate dihydrate; dextran 40 - indications: for use in the treatment of: *small cell carcinoma of the lung *acute monocytic and myelomonocytic leukaemia *hodgkin's disease *non-hodgkin's lymphoma *testicular tumours.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide phosphate, quantity: 567.8 mg (equivalent: etoposide, qty 500 mg) - injection, powder for - excipient ingredients: sodium citrate dihydrate; dextran 40 - indications: for use in the treatment of: *small cell carcinoma of the lung *acute monocytic and myelomonocytic leukaemia *hodgkin's disease *non-hodgkin's lymphoma *testicular tumours.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide phosphate, quantity: 113.6 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; dextran 40 - for use in the treatment of: small cell carcinoma of the lung; acute monocytic and myelomonocytic leukaemia; hodgkin's disease; non- hodgkin's lymphoma and testicular tumours.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 100 mg - capsule - excipient ingredients: iron oxide red; gelatin; purified water; glycerol; sodium propyl hydroxybenzoate; citric acid; sodium ethyl hydroxybenzoate; titanium dioxide; macrogol 400 - 1 - small cell carcinoma of the lung 2 - acutre monocytic and myelomoncytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphoma indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - etoposide, quantity: 50 mg - capsule - excipient ingredients: sodium propyl hydroxybenzoate; glycerol; sodium ethyl hydroxybenzoate; citric acid; iron oxide red; gelatin; titanium dioxide; macrogol 400; purified water - 1 - small cell carcinoma of the lung 2 - acute monocytic and myelomonocytic leukaemia 3 - hodgkins disease 4 - non-hodgkins lymphonia indications as at 5 october 2000: in the treatment of: 1. small cell carcinoma of the lung. 2. acute monocytic and myelomonocytic leukaemia. 3. hodgkin's disease. 4. non-hodgkin's lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

purple products pty ltd -